Skip to content

Zymeworks ZYME Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$7.19M+20.5%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$347.72M+430%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$412.55M+77,887%
Pfizer logo
PfizerPFE
Amgen logo
AmgenAMGN
Summit Therapeutics logo
Summit TherapeuticsSMMT

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's cash provided by (used in) financing activity, including discontinued operation?
Zymeworks (ZYME) reported cash provided by (used in) financing activity, including discontinued operation of $178.79M in Q1 2026.
How has Zymeworks's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
Zymeworks's cash provided by (used in) financing activity, including discontinued operation increased by 13485.6% year-over-year, from $1.32M to $178.79M.
What is the long-term trend for Zymeworks's cash provided by (used in) financing activity, including discontinued operation?
Over 2 years (2023 to 2025), Zymeworks's cash provided by (used in) financing activity, including discontinued operation has grown at a -52.4% compound annual growth rate (CAGR), from $81.87M to -$18.56M.
What does cash provided by (used in) financing activity, including discontinued operation mean?
This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.